Regulatory and Reimbursement Harmonization

Slides:



Advertisements
Similar presentations
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Advertisements

Outcomes of the 2008 Conference and Work of the Access to Medicines Working Group Will Delaat David Learmonth ChairmanDeputy Secretary Medicines AustraliaDepartment.
Portugal Economic Evaluation Applied to Decision Making Isaura Vieira INFARMED, I.P. – National Authority for Medicines and Health Products I Pan-American.
The evolving role of real-world evidence to support policy and practice CADTH 2015.
CADTH Therapeutic Reviews
HTA from an Industry Perspective Janey Shin, Director of Medical Affairs Johnson & Johnson Medical Companies CADTH, 2015.
The Role of Patients in Defining “value” and Engaging in Drug Development from Bench to Bedside 1 CADTH Conference Concurrent Session A5 April 13, 2015.
The Canadian Top 10 Watch List of New and Emerging Health Technologies Alain Boisvert, M.Sc (Pharm.) Vice-President, Market Access & Public Affairs April.
CADTH – CNESH Panel Presentation Representing Canada’s Medical Technology Industry April 13 th, 2015 Alison Drinkwater: Director of Public Affairs Baxter.
HTA & Medical Devices: An International Perspective Christina Farup, MD, MS | April 2015.
Michelle Boudreau, Vice President, Private Markets, March 11, 2015 Presentation to CADA.
Biopharmaceutical Regulatory Requirements 40. Marketing Authorization for New Chemical Entities Health Canada’s (HC) Therapeutic Products Directorate.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.
Andrew Gettinger, MD, FCCP, FCCM CMIO, Office of the National Coordinator for HIT Director (acting), Office of Clinical Quality and Safety Health IT Safety.
Right Drug, Right Person, Right Price: Improving and Governing the Provincial Drug System Helen Stevenson Executive Lead, Drug System Secretariat Ministry.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
CHALLENGES FOR PRAGMATIC TRIALS IN EUROPE Donna A. Messner, PhD.
SMC Horizon Scanning Anne Lee, Scottish Medicines Consortium Julia Earnshaw, GlaxoSmithKline.
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
1 Evaluating & Applying What Works Best Leaders’ Project Policy Forum Kathy Buto, VP Health Policy April 24, 2008.
Adaptive Licensing UK. Content What is adaptive licensing? Draft criteria for pilot candidate selection EMA Road Map 2015 and work programme 2012 UK perspective.
SOUTHERN AFRICAN REGIONAL PROGRAMME ON ACCESS TO MEDICINES AND DIAGNOSTICS PROCESS & CHALLENGES OF WORKING REGIONALLY IN SOUTHERN AFRICA AARTI PATEL WHO.
© Safeguarding public health Can Europe grow its Medtech industry and lead the world on medical device regulation? John Wilkinson 20 th September 2012.
An Introduction to Genetic Alliance UK’s Work in Scotland Natalie Frankish – Development Officer for Scotland Event:Action Duchenne Scottish Conference.
Risk Sharing Schemes Dr Rafiq Hasan Director of Market Access
SMC and the role of Public Involvement Action Duchenne Scottish Mini Conference 4 December 2015 Lindsay Lockhart Public Involvement Officer.
European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Public hearings.
Process mapping of registration to reimbursement for new pharmaceuticals in UK.
Science is leading the revolution in targeted, personalised therapies:
Health Technology Assessment for Pharmaceuticals and New Medical Technologies - Where are we now? The industry perspective Jenny Hughes, Director, Vaccines.
DEVELOPING TALENT GROWING VENTURES OPENING MARKETS Visit us at marsdd.com From HTA recommendatio n to adoption at scale APRIL 11, 2016 Zayna Khayat, Ph.D.
Liberating the NHS: Developing the healthcare workforce Workforce planning, education and training Consultation Engagement.
Gwendolyn Ryals, Look at Me Artwork from The Creative Center Janey Shin, Director, Real World Evidence Government Affairs and Market Access CADTH Symposium.
Evolving Practices in the Assessment of Medical Devices An Industry Perspective Adrian Griffin | April 2016.
Regulatory and Reimbursement Harmonization An Industry Perspective Adrian Griffin | April 2016.
Cancer Drug Funding Sustainability: From Recommendations to Action CADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs.
Aligning Policy Agendas The case of personalised care and cure for healthy and active ageing Setting the scene for the DG Regio and Flanders Smart Specialisation.
Patient Engagement throughout the Biopharmaceutical Lifecycle: Tips for Effective Patient Advocate/Industry Collaboration to Improve Patient Access and.
Real World Evidence in Cancer Care: A Payer’s Perspective CADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs.
CADTH Symposium The speaker has no financial or other conflicts of interest to report.
Continuous Improvement & Real World Evidence: A Public Payer’s Perspective Suzanne McGurn, Assistant Deputy Minister and Executive Officer Ontario Public.
Patient Engagement in Drug Development: Experiences, Good Practices and Lessons Learned Lana Skirboll VP Science Policy Sanofi October 28, 2016, National.
Perspectives for the New-in-Practice Physician
Taxonomy of Strategies
Australian Jurisdictional Update March 2017
MEP Interest Group on Brain, Mind and Pain
February 2017 Demystifying Georgia Tech
Craig Earle, MD MSc FRCPC
Successes in Achieving Health and Human Services Equity in Minnesota
Cornerstone Research Group Inc.
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
Better Science, Better Health: New Healthcare Models
Lessons Learned Through HBD: The Regulator’s View - US FDA
. Regulatory Approach to Subsequent Entry Biologics in Canada
New economies: Scenarios with a likelihood >50% and impact
Strategic & Operational Planning:
Oncology Care Model 2.0 The Universal Payment Model in Oncology
Harmonization for Patient Centered Universal Health Coverage
Kaisa Immonen EPF Director of Policy
Median, Box : 25th and 75th percentiles
Germany’s Approach to Prescription Drug Pricing
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Ontario Industrial EPS Proposal IETA Insights for Ontario Stakeholders Clean Economy Alliance Webinar 15 March 2019 Toronto, Canada.
Session 3: Coverage and Reimbursement for Genetic Testing
EUnetHTA Assembly May 2018.
Germany’s Approach to Prescription Drug Pricing
Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.
An Agency Perspective on Plain Language Summaries of Publications
Patients and Families Statement
Presentation transcript:

Regulatory and Reimbursement Harmonization Brent Fraser VP, Pharmaceutical Reviews April 11, 2016

Current State Regulatory HTA Payer Flexible licensing pathways Adaptive licensing Funding recommendations to public drug plans based on clinical and cost effectiveness and patient input. Pre-NOC submissions Funding agreements - Finance models - Managed entry agreements - Coverage w/ evidence development

Why Change? Access: Therapeutic need Managing expectations post market approval Increasing certainty: Time to decision Health Canada approval Funding decision Partially addressed through regulatory and HTA processes

What’s Missing Regulatory HTA Payer Managing issues along the continuum to drug access Many voices including the payer, patients and clinicians

Opportunities Innovative approaches arising from collaborative work in Europe and the US Medicines Adaptive Pathways to Patients (MAPPs) ADAPTSMART Public / Private partnerships Huge opportunity for lessons learned

Are “we” Stalled? Is the “trust” strong enough to have these conversations in a safe environment in order to find solutions? We need to ensure some of level of transparency within this work. Are we willing to accept real world effectiveness data in decision making? Who collects the data? Who funds the collection? When do we collect the data and what do we do with it once we get it? Does Canada have the infrastructure to support this work? How do we get started? How do we ensure all voices are heard? How do we include other pan-Canadian entities as appropriate? Is this for all drugs or some drugs?

Things We’re Doing Now Identifying opportunities for joint discussions. Identifying issues earlier in the review process. Earlier engagement with manufacturers. pCODR clinician engagement.